RU2672252C1 - Новые 3-индол замещенные производные, фармацевтические композиции и способы применения - Google Patents

Новые 3-индол замещенные производные, фармацевтические композиции и способы применения Download PDF

Info

Publication number
RU2672252C1
RU2672252C1 RU2017130845A RU2017130845A RU2672252C1 RU 2672252 C1 RU2672252 C1 RU 2672252C1 RU 2017130845 A RU2017130845 A RU 2017130845A RU 2017130845 A RU2017130845 A RU 2017130845A RU 2672252 C1 RU2672252 C1 RU 2672252C1
Authority
RU
Russia
Prior art keywords
fluoro
indol
methyl
dihydrobenzo
dioxide
Prior art date
Application number
RU2017130845A
Other languages
English (en)
Russian (ru)
Inventor
Саша Нинкович
Стефано Крозиньяни
Стефани Энн СКЕЙЛЗ
Индраван Джеймс Макалпин
Майкл Рэймонд Коллинс
Андреас Мадерна
Мартин УАЙТС
Original Assignee
Пфайзер Инк.
Айтеос Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2015/051957 external-priority patent/WO2015140717A1/en
Application filed by Пфайзер Инк., Айтеос Терапьютикс filed Critical Пфайзер Инк.
Application granted granted Critical
Publication of RU2672252C1 publication Critical patent/RU2672252C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2017130845A 2015-03-17 2016-03-17 Новые 3-индол замещенные производные, фармацевтические композиции и способы применения RU2672252C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2015/051957 WO2015140717A1 (en) 2014-03-18 2015-03-17 Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
IBPCT/IB2015/051957 2015-03-17
US201562203032P 2015-08-10 2015-08-10
US62/203,032 2015-08-10
PCT/IB2016/051509 WO2016147144A1 (en) 2015-03-17 2016-03-17 Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Publications (1)

Publication Number Publication Date
RU2672252C1 true RU2672252C1 (ru) 2018-11-13

Family

ID=56919874

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017130845A RU2672252C1 (ru) 2015-03-17 2016-03-17 Новые 3-индол замещенные производные, фармацевтические композиции и способы применения

Country Status (14)

Country Link
US (1) US9873690B2 (enExample)
EP (1) EP3271354A1 (enExample)
JP (1) JP6775516B2 (enExample)
KR (1) KR102013512B1 (enExample)
CN (1) CN107635990A (enExample)
AU (1) AU2016231832B2 (enExample)
BR (1) BR112017019699A2 (enExample)
CA (1) CA2979616C (enExample)
HK (1) HK1243999A1 (enExample)
IL (1) IL254124A0 (enExample)
MX (1) MX2017011951A (enExample)
RU (1) RU2672252C1 (enExample)
SG (1) SG11201706992TA (enExample)
WO (1) WO2016147144A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160336813A1 (en) 2015-05-15 2016-11-17 NeuSpera Medical Inc. Midfield coupler
EP4074273A1 (en) 2014-05-18 2022-10-19 NeuSpera Medical Inc. Midfield coupler
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3554494A4 (en) 2016-12-19 2021-02-17 Cellixbio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3060989A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2019075359A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS AND METHODS OF USE
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN111166735B (zh) * 2020-01-15 2023-08-18 延边大学 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
JP7296017B2 (ja) 2020-04-30 2023-06-21 メッドシャイン ディスカバリー インコーポレイテッド ベンゾスルタムを含む化合物
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
CN111777557B (zh) * 2020-07-28 2022-11-22 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN119707855A (zh) * 2024-12-20 2025-03-28 西南大学 一种光学活性胺类衍生物及其不对称烷基化合成方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050963A1 (en) * 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
CN101265259A (zh) * 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
EA201170161A1 (ru) * 2008-07-08 2011-08-30 Инсайт Корпорейшн 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509731C2 (sv) 1996-05-14 1999-03-01 Labwell Ab Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi
JP2000095759A (ja) 1998-07-21 2000-04-04 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
BR0212613A (pt) 2001-09-19 2004-08-31 Pharmacia Corp Compostos de indazol substituìdos para o tratamento de inflamação
DE60331219D1 (de) 2002-03-28 2010-03-25 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1606285A4 (en) * 2003-03-27 2009-03-18 Lankenau Inst Medical Res NEW IDO HEMMER AND APPLICATION PROCEDURES
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0328909D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1805171A4 (en) * 2004-09-21 2009-05-13 Wyeth Corp CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF
NZ560225A (en) 2005-02-09 2010-10-29 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
WO2007039580A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted benzophenone compounds
WO2007045622A1 (en) 2005-10-18 2007-04-26 Nycomed Gmbh Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors
CN101374808B (zh) 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
KR20080108517A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
GB0624308D0 (en) 2006-12-05 2007-01-17 Molmed Spa Combination product
US8058272B2 (en) 2006-12-07 2011-11-15 Novartis Ag Organic compounds
CA2677096A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
CA2694224A1 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
US20110159017A1 (en) 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
WO2010096389A1 (en) 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
AU2010298168B2 (en) 2009-09-23 2015-11-19 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
BR112012006956A2 (pt) 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
CN103282034A (zh) 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
US9273029B2 (en) 2011-05-23 2016-03-01 Merck Patent Gmbh Pyridine-and pyrazine derivatives
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
US20160263087A1 (en) 2013-11-08 2016-09-15 Iteos Therapeutics Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
JP2017505346A (ja) 2014-02-12 2017-02-16 アイティーオス セラペウティクス 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
US20150266857A1 (en) * 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CA2942761A1 (en) * 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
SG11201608708WA (en) 2014-05-15 2016-11-29 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
CA2994917A1 (en) * 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101265259A (zh) * 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
WO2007050963A1 (en) * 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
EA201170161A1 (ru) * 2008-07-08 2011-08-30 Инсайт Корпорейшн 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOLUSIC E. et al, Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012), Expert Opin. Ther. Patents, 2013, v. 23, no. 10, p. 1367-1381. *
DOLUSIC E. et al, Tryptophan 2,3-Dioxygenase (TDO) Inhibitors 3-(2-Pyridyl)ethenyl)indoles as Potential Anticanser Immunomodulators, J. Med. Chem., 2011, v. 54, no. 15, p. 5320-5334. *
DOLUSIC E. et al, Tryptophan 2,3-Dioxygenase (TDO) Inhibitors 3-(2-Pyridyl)ethenyl)indoles as Potential Anticanser Immunomodulators, J. Med. Chem., 2011, v. 54, no. 15, p. 5320-5334. DOLUSIC E. et al, Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012), Expert Opin. Ther. Patents, 2013, v. 23, no. 10, p. 1367-1381. *

Also Published As

Publication number Publication date
CA2979616C (en) 2020-04-28
US9873690B2 (en) 2018-01-23
KR102013512B1 (ko) 2019-08-22
KR20170132204A (ko) 2017-12-01
US20160272628A1 (en) 2016-09-22
BR112017019699A2 (pt) 2018-09-04
AU2016231832B2 (en) 2019-09-19
JP6775516B2 (ja) 2020-10-28
WO2016147144A1 (en) 2016-09-22
EP3271354A1 (en) 2018-01-24
CN107635990A (zh) 2018-01-26
CA2979616A1 (en) 2016-09-22
AU2016231832A1 (en) 2017-09-14
SG11201706992TA (en) 2017-09-28
MX2017011951A (es) 2018-06-15
IL254124A0 (en) 2017-10-31
JP2018511587A (ja) 2018-04-26
HK1243999A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
RU2672252C1 (ru) Новые 3-индол замещенные производные, фармацевтические композиции и способы применения
US10544095B2 (en) 3-indol substituted derivatives, pharmaceutical compositions and methods for use
KR102122357B1 (ko) 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
US9126984B2 (en) 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
JP2017505346A (ja) 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
US20160263087A1 (en) Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
WO2015140717A9 (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
TW201930315A (zh) 具抗b型肝炎病毒(hbv)活性之新穎高活性胺基-噻唑取代之吲哚-2-甲醯胺
JP7162591B2 (ja) スピロピペリジン誘導体
TW201819362A (zh) 作為吲哚胺2,3-二氧酶調節劑的經取代n-羥基甲脒基雜環化合物
CA2929650C (en) 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP4126849A1 (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists
CN119855589A (zh) 杂环pad4抑制剂
CN119604287A (zh) 杂环pad4抑制剂

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210318